Alpha 2.0
Login Register
» Authors » Mark Frydenberg

Mark Frydenberg

Explore the profile of Mark Frydenberg including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 196
Citations 4776
Followers 0
Related Specialties
Urology
Oncology
General Medicine
Top 10 Co-Authors
Declan G Murphy
Gail P Risbridger
Ian D Davis
Renea A Taylor
Nathan Lawrentschuk
Daniel Moon
Jeremy Grummet
Jeremy Millar
Mitchell G Lawrence
Andrew Ryan
Published In
BJU Int
Eur Urol
ANZ J Surg
Psychooncology
Eur Urol Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol
Wegener E, Ng M, Guerrieri M, Showalter T, de Leon J, Ramani S, et al.
BMC Cancer . 2025 Feb; 25(1):250. PMID: 39948585
Background: Androgen deprivation therapy (ADT) improves outcomes in men undergoing definitive radiotherapy for prostate cancer but carries significant toxicities. Clinical parameters alone are insufficient to accurately identify patients who will...
2.
Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance
de Vos I, Nieboer D, Frydenberg M, Pavlovich C, Van Hemelrijck M, Lee L, et al.
JAMA Netw Open . 2025 Jan; 8(1):e2454366. PMID: 39820695
Importance: Active surveillance (AS) for patients with prostate cancer (PC) often includes fixed repeat prostate biopsies that do not account for the varying risk of reclassification to significant disease. Given...
3.
Baseline Nodal Status on Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial
Hofman M, Kasivisvanathan V, Link E, Buteau J, Roberts M, Francis R, et al.
Eur Urol Oncol . 2024 Nov; PMID: 39613566
Background And Objective: There is uncertainty regarding the clinical significance of Ga-PSMA-11 positron emission tomography (PET) computed tomography (CT) findings in men with prostate cancer. In this prespecified objective of...
4.
Using large administrative data for mining patients' trajectories for risk stratification: An example from urological diseases
Koh H, Gasevic D, Rankin D, Frydenberg M, Talic S
PLoS One . 2024 Nov; 19(11):e0310981. PMID: 39536022
Objective: To identify latent clusters among urological patients by examining hospitalisation rate trajectories and their association with risk factors and outcome quality indicators. Materials And Methods: Victorian Admitted Episodes Dataset,...
5.
Variational Bayes machine learning for risk adjustment of general outcome indicators with examples in urology
Koh H, Gasevic D, Rankin D, Heritier S, Frydenberg M, Talic S
NPJ Digit Med . 2024 Sep; 7(1):249. PMID: 39277683
Risk adjustment is often necessary for outcome quality indicators (QIs) to provide fair and accurate feedback to healthcare professionals. However, traditional risk adjustment models are generally oversimplified and not equipped...
6.
Cost-utility Analysis of Navigate, a Treatment Decision Aid for Men with Prostate Cancer and Their Partners, in Comparison to Usual Care
Lindsay D, Schofield P, Roberts M, Yaxley J, Quinn S, Richards N, et al.
Eur Urol Oncol . 2024 Aug; PMID: 39181775
Background And Objective: Evidence on the cost effectiveness of decision aids to guide management decisions for men with prostate cancer is limited. We examined the cost utility of the Navigate...
7.
Standardized template for clinical reporting of PSMA PET/CT scans
Esfahani S, Morris M, Sartor O, Frydenberg M, Fanti S, Calais J, et al.
Eur J Nucl Med Mol Imaging . 2024 Aug; 52(1):335-341. PMID: 39143250
Purpose: Accurate diagnosis and staging of prostate cancer are crucial to improving patient care. Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography with computed tomography (PET/CT) imaging has demonstrated superiority for...
8.
Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry
Bangma C, Doan P, Zhu L, Remmers S, Nieboer D, Helleman J, et al.
Eur Urol Oncol . 2024 Jul; PMID: 39025687
Background And Objective: Active surveillance (AS) has evolved into a widely applied treatment strategy for many men around the world with low-risk prostate cancer (or in selected cases intermediate-risk disease)....
9.
Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial
See A, Conway P, Frydenberg M, Haxhimolla H, Costello A, Moon D, et al.
Int J Cancer . 2024 Jun; 155(7):1248-1256. PMID: 38898626
Metastasis-directed therapy (MDT) for oligometastatic prostate cancer (PCa), including stereotactic body radiotherapy (SBRT), has shown promise but is still considered investigational. This is the 5-year analysis of the TRANSFORM trial,...
10.
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite...
Emmett L, Papa N, Hope T, Fendler W, Calais J, Burger I, et al.
J Urol . 2024 May; 212(2):299-309. PMID: 38758680
Purpose: The Prostate Imaging Reporting and Data System (PI-RADS) score is standard of care for clinically significant prostate cancer (csPCa) diagnosis. The PRIMARY score (prostate-specific membrane antigen [PSMA]-positron emission tomography...